{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-031202","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.912991+00:00","generated_at":"2026-05-30T14:34:51.952048+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Genprex completes 0.09 mg/kg dose in Phase 1 Acclaim-3 trial; SRC approves escalation to highest dose","bullets":["Completed 0.09 mg/kg dose group of Reqorsa + Tecentriq in ES-SCLC Phase 1; no dose-limiting toxicities reported.","Safety Review Committee approved escalation to 0.12 mg/kg, the highest planned dose group.","Phase 2 expansion will enroll 50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.","Acclaim-3 has FDA Fast Track and Orphan Drug Designations for this patient population.","Company expects to start Phase 2 expansion in H2 2024, pending enrollment in the 0.12 mg/kg cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-031202","json":"https://secwatch.observer/filing/0001437749-24-031202.json","markdown":"https://secwatch.observer/filing/0001437749-24-031202.md","text":"https://secwatch.observer/filing/0001437749-24-031202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924031202/0001437749-24-031202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924031202/gnpx20241009_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:34:51.952048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}